


Thalidomide-4-O-C6-NH2

Cat. No.:	HY-135250
CAS No.:	1957235-98-1
Molecular Formula:	C ₁₉ H ₂₃ N ₃ O ₅
Molecular Weight:	373.4
Target:	E3 Ligase Ligand-Linker Conjugates; Apoptosis; Autophagy
Pathway:	PROTAC; Apoptosis; Autophagy
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Thalidomide-4-O-C6-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology ^[1] .
IC ₅₀ & Target	Cereblon
In Vitro	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Erb MA, et al. Transcription control by the ENL YEATS domain in acute leukaemia. *Nature*. 2017 Mar 9;543(7644):270-274.
- [2]. Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine. *Front Cell Dev Biol*. 2021;9:629326. Published 2021 Mar 11.
- [3]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. *Cell Chem Biol*. 2020;27(8):998-985.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA